Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

November 7, 2023

NASDAQ US Health Care Biotechnology earnings 32 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks, operator, and good afternoon to all of you. We appreciate your participation in this conference call covering Corvus Pharmaceuticals' business update and financial results for the third quarter of 2023. Here to go over the results and business developments are Richard Miller, our Chief Executive Officer, Leiv Lea, our Chief Financial Officer, James Rosenbaum, Senior Vice President of Research, and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. After some prepared remarks from the executive team to kick things off, we'll move into a question and answer session. Everyone should be aware that management's comments today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus's quarterly report on Form 10-Q, filed today with the SEC, as well as other filings the company periodically makes with the SEC. Except where the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'd like to hand the call over to Leiv. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a brief look at how our finances came out for the third quarter of 2023, and after that I'll hand things over to Richard so he can walk everyone through the business update. When it came to research and development, our expenses for Q3 2023 came to $4 million, which compares with $10.4 million during the same quarter in 2022. That $6.4 million drop was mostly driven by reduced clinical trial and manufacturing costs tied to developing mupadolimab, our anti-CD73 antibody. We posted a net loss of $6 million in the third quarter of 2023, and that figure includes a $0.9 million non-cash loss connected to Angel Pharmaceuticals, our partner in China; for the same period in 2022, the net loss stood at $14.8 million, which had included a $2.7 million non-cash loss tied to Angel Pharmaceuticals. Total stock compensation expense came in at $0.5 million for the third quarter of 2023, versus $0.7 million during the comparable period in 2022. On September 30, 2023, Corvus held cash, cash equivalents, and marketable securities amounting to $32.2 million, compared with $42.3 million on December 31, 2022. Turning to what lies ahead, we anticipate that net cash used in operating activities for the full year 2023 will land somewhere between $22 million and $23 million, which would leave us with a projected cash balance somewhere between $27 million and $28 million on December 31, 2023. As we mentioned last quarter, we keep managing our cash burn rate carefully by concentrating on the opportunities that look most promising and by setting up collaborations that assist in supporting development of our product candidates. Given that trend, along with our present plans and our emphasis on soquelitinib, we believe our cash will give us runway into late 2024. At this point I'll pass the call to Richard, who will go over our clinical progress and provide more detail on our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and good afternoon to all of you. We appreciate your joining today's call on our business update. We're still seeing outstanding strides in developing soquelitinib, our selective ITK inhibitor, which offers a platform possibility spanning blood cancers, solid tumors, immune-mediated conditions, and immune-mediated disorders. Since the earnings call we held in early August, here are the key milestones we've hit. First, we held a meeting with the FDA — an end-of-phase, pre-phase III discussion — to go over and examine registration strategies for soquelitinib as a therapy for relapsed peripheral T-cell lymphoma, or PTCL. Second, during that meeting, we secured alignment and consensus regarding our strategy for a registration phase III study. After that, we sent a finalized, full protocol to the FDA, and at this point we possess every FDA regulatory allowance needed to launch the clinical study. Third, alongside our work with the FDA, we kept up recruitment of top academic sites for the study, and those sites are now moving through the standard contract and Institutional Review Board approval steps. Fourth, regarding our continuing clinical program, we maintained enrollment and follow-up of patients in our Phase I/Ib study of soquelitinib and T-cell lymphoma, and an abstract was accepted for a poster presentation at the ASH meeting in December. Fifth, turning to the soquelitinib opportunity in solid tumors, we achieved alignment with investigators at the Kidney Cancer Research Consortium on a protocol to assess soquelitinib monotherapy in patients with recurrent renal cell cancer who have failed checkpoint inhibitor therapy. Sixth, beyond oncology, we posted a preprint on bioRxiv showing research carried out by an international group of scientists-... demonstrating strong activity of soquelitinib across several animal models of immune diseases, along with a description of a novel mechanism offering the rationale for the potential usefulness of ITK inhibition in multiple inflammatory immune-mediated diseases. Finally, we kept enrolling in the Phase II portion of a Phase I/II trial with ciforadenant, in combination with ipilimumab and nivolumab, in relapsed renal cell cancer. Now I'll give more detail on a few of these achievements, beginning with our advancement toward the Phase III registration clinical trial of soquelitinib in PTCL. Since the update call we held in early September, we've refined the study protocol so it incorporates FDA feedback. We recently completed the study protocol and sent it to the FDA. I can verify there were no major modifications compared with what we proposed regarding the trial design or our registration strategy and plans. From a regulatory standpoint, we are cleared to begin the trial. In brief, the trial was designed to enroll 150 patients in total with relapsed PTCL, 75 patients per arm, who have received 1 to less than or equal to 3 prior therapies. The limit on the number of prior therapies matters because it also pinpoints immunocompetent patients, meaning those whose absolute lymphocyte counts are above 900. Patients will be randomized to get soquelitinib, 200 milligrams, 2 times a day, or the standard of care chemotherapy agents. For the control arm, the physician will choose among pralatrexate, belinostat, or gemcitabine. Progression-free survival, as assessed by an independent review committee, will serve as the primary endpoint. Objective response rate and overall survival will be among the secondary endpoints. An interim analysis is also going to be part of the study. If statistical significance is reached and the trial is conducted well, our study ought to back FDA approval. While we finish the protocol, we've been signing up investigators for this study. A number of top centers across the United States have shown tremendously strong enthusiasm for joining the study, and right now we're working through contracts, obtaining IRB approvals, and handling the other typical steps required to get the study underway. The caliber of centers involved so far illustrates the U.S. site interest, and it includes Memorial Sloan Kettering, Stanford, Dana-Farber, UCSF, City of Hope, MD Anderson, Fred Hutchinson Cancer Center, and many others. Because U.S. centers are so interested, we have less need to use sites outside the U.S. In our view, more participation from US sites brings several benefits, such as better control over data quality, a stronger package for regulatory approval in the US, lower execution risk, and lower cost. Roughly 40 centers are expected to take part in the trial. The United States will account for the vast majority. Progress is good on every front, and we expect to be able to launch the soquelitinib Phase III trial by the second quarter of 2024. We're also carrying on with the Phase I/Ib clinical trial in T-cell lymphoma. Together with collaborators at the Beijing Cancer Center, we intend to present further data from the Phase I/Ib clinical trial of soquelitinib in T-cell lymphoma, plus correlative data, in a poster presentation at the ASH meeting in December; relatedly, evidence keeps growing that supports the potential of selective ITK inhibition in oncology. Back in July, we published our preclinical data on soquelitinib, which emphasized its potential to boost antitumor immune response to hematologic and solid tumors and to offer a novel approach to cancer immunotherapy. In September, an independent academic group led by a team from Erasmus University Medical Center in Rotterdam, published a paper confirming and extending the potential of ITK inhibition for the treatment of solid tumors. Those preclinical and laboratory results matched our preclinical and clinical data on soquelitinib and offer further evidence confirming the potential of selective ITK inhibition to strengthen immune responses to solid tumors; we remain on track for the initiation of a Phase Ib/II solid tumor clinical trial in relapsed renal cell cancer in early 2024. I'll now hand the call over to Dr. James Rosenbaum to review recent developments for soquelitinib in inflammatory and immune diseases.

James Rosenbaum

executive
#4

Richard, thanks. A fairly striking thing we've found with the ITK inhibitor platform is the steady accumulation of data backing its promise as a brand-new therapeutic avenue for a wide array of immune-mediated conditions. Results went up on bioRxiv last week that lend support to ITK inhibition's potential across multiple preclinical models — acute asthma, chronic asthma, psoriasis, pulmonary fibrosis, scleroderma, and graft versus host disease among them. That paper sits on our website, and inside it you'll find a thorough examination of the data behind every one of those models. What matters most: blocking ITK selectively halts the creation of T cells that play a central part in the pathophysiology of numerous immune-mediated diseases. Our view is that soquelitinib, along with our second and third generation ITK inhibitors, addresses the underlying driver of many such diseases by shutting down production of a broad spectrum of inflammatory cytokines made by those cells. To put a finer point on it, the mechanism of action laid out in the paper entails blocking differentiation of TH2 and TH17 cells and then inhibiting the cytokines they produce, things like interleukin-4, IL-5, IL-13, and IL-17. Those same cytokines are the targets of many established, successful medicines spanning various medical categories and indications. Soquelitinib and ITK inhibition offer a small molecule, orally administered, targeted strategy featuring a novel mechanism that acts upstream to block generation of multiple inflammatory mediators. Meanwhile, soquelitinib leaves TH1 cells alone, and those cells are essential for fighting infection. Because of that, we have not seen opportunistic infection to date in our lymphoma trial, where patients being treated have compromised immune systems. As mentioned before, the activity of soquelitinib and our other second and third generation compounds gets amplified by blocking the T cells that produce multiple mediators. Compare that with giving a soluble receptor or antibody that blocks just one cytokine — that's a stoichiometric, or one-to-one, relationship, rather than blocking the source of multiple cytokine production. I'd urge you to look over the paper and the press release that goes with it for the details. Richard, I'll hand the call back to you now.

Richard Miller

executive
#5

Thanks, Jim. Because ITK inhibition could have wide-ranging uses in inflammatory and immune-mediated conditions, our strategy is to team up with biotech or pharma organizations whose development and commercialization strengths align with these different opportunities. We feel confident about drawing partners in, thanks to the distinctive aspects of ITK inhibition, the human safety data we generated for soquelitinib in our lymphoma studies, the sizable and varied market opportunities, and our robust intellectual property estate. Cancer remains a key focus, an area where we possess expertise and a demonstrated record of accomplishment. Now to our partner-led programs: the Kidney Cancer Research Consortium is presently enrolling patients in the phase II portion of a phase Ib/II clinical trial that is assessing ciforadenant, our A2A receptor inhibitor, as a possible first-line treatment for metastatic renal cell cancer alongside ipilimumab and nivolumab. Up to 60 patients are expected to be enrolled in this clinical trial, and according to current timelines, we expect initial interim data in early 2024. Right now, I'm happy to share that the deep response rate is above our 32% benchmark, measured across 8 evaluable patients who have had at least one follow-up assessment. As a reminder, deep response rate means complete responses plus partial responses with more than 50% tumor volume reduction; others have demonstrated that this endpoint predicts prolonged progression-free survival, and it stands at 32% with the Ipi-Nivo combination; regarding mupadolimab, our partner Angel Pharmaceuticals is still enrolling patients in a phase I/Ib clinical trial in China, testing mupadolimab as a single agent and in combination with pembrolizumab in patients who have non-small cell lung cancer and head and neck squamous cell cancers. All things considered, we have numerous opportunities with several forthcoming catalysts throughout our pipeline, anchored by our foundational efforts on ITK inhibition and its countless biologic activities within the immune system. Across the rest of this year and into 2024, our forthcoming milestones include new interim data from the phase I/Ib clinical trial of soquelitinib and T-cell lymphoma at the ASH meeting in December, launching the soquelitinib phase III registration clinical trial by the second quarter of 2024, launching a phase Ib/II solid tumor monotherapy trial of soquelitinib in relapsed renal cell cancer in early 2024, and initial interim data from the ciforadenant phase Ib/II trial in frontline metastatic RCC in early 2024. Let me recap a few points. Corvus has a pipeline of novel products targeting large markets across diverse areas of cancer and immune diseases. We are moving forward along the clinical development pathway, with one indication poised to enter a phase III registration trial. We have managed our cash prudently while effectively advancing our products. The breadth of indications and products creates potential partnering opportunities; to close, we look forward to sharing updates on our programs in the quarters ahead. I'll now hand the call over to the operator for questions and answers.

Aydin Huseynov

analyst
#6

Hello there, good afternoon, Richard, and to the whole Corvus team. Congrats on the quarterly results and on the progress being made. I've got a few questions. Turning to the ASH conference that's coming up next month, could you give us a sense of the kind of data we should be expecting there? As I recall, Corvus previously reported 43% ORR, 6 out of 14 responses, disease control rate 86%. But how much additional patient data do you intend to report at ASH? And do you anticipate the ORR numbers shifting in either direction?

Richard Miller

executive
#7

Is that your first question or your second one?

Aydin Huseynov

analyst
#8

Um, it's-

Richard Miller

executive
#9

Okay.

Aydin Huseynov

analyst
#10

This will combine two questions into one.

Richard Miller

executive
#11

Let me handle the initial one. That initial question — what will we be presenting at the ASH meeting? Well, the poster and its abstract were handed in jointly with our partners at Peking University, Beijing Cancer Center. Their main emphasis was single-cell RNA sequencing, used to shed light on how soquelitinib works. Through multiple biopsy and blood samples, they have been verifying that we truly do bring about these TH1 cells while blocking TH2 and TH17, resulting in a greater number of cytolytic T cells — more or less what you have already been told. Alongside that, Corvus plans to put out a press release giving a clinical data update. A few items will go into that update. The first is patients, how many responses, stable disease along with durations, waterfalls, swimmers; we are also including — since people raised the question — absolute lymphocyte count compared with relying on prior therapies to pin down appropriate or eligible candidates for our Phase III trial. Data on that will be shown as well. So a major shift in response rate isn't something I anticipate; our follow-up is longer now. More or less, I'd say our response rate and how long responses last remain steady and are continuing to hold.

Aydin Huseynov

analyst
#12

Thanks, and thanks, Richard. That's useful. As for those CRs and PRs we heard about before, do they remain ongoing?

Richard Miller

executive
#13

My sense is the length of time involved hasn't shifted much. The CR, I'm sure, is still going, without a doubt, and it's now sitting at roughly 21 months. As for how long it's been for the rest of those patients, I simply can't recall that detail right off the top of my head.

Aydin Huseynov

analyst
#14

Got it, that makes sense. Fine.

Richard Miller

executive
#15

Then one more thing — Richard Miller (A): Aydin, hold on, let me just—

Aydin Huseynov

analyst
#16

Yeah.

Richard Miller

executive
#17

I'd like to note that our responses hold up quite well over time, and I believe you've touched on something quite significant, since what's been striking about the standard therapies is how brief their periods of disease control have been.

Aydin Huseynov

analyst
#18

All right, all right, that's useful. Then I'd like to ask about soquelitinib and how the renal cancer monotherapy study is designed. Clearly, with any single-agent approach, everyone is looking for ORR. So in renal cancer, what minimum ORR bar do you have in mind? Should we anticipate response rates along the lines of what appeared in PTCL, or is this a somewhat distinct disease where the bar sits elsewhere?

Richard Miller

executive
#19

Honestly, that's tough to respond to when we don't yet know precisely which patients will enroll; eligibility requires prior failure of a checkpoint inhibitor. And since one or two earlier lines of therapy are permitted, patient selection will matter a great deal. Still, Aydin, I'd argue that any responses seen in someone who has relapsed after a CTLA-4 or PD-1 would stand out. My view is that a 15% response rate from monotherapy in that population, with a new mechanism of action and an oral drug that's fairly well tolerated, would represent a major advance. In the end, of course, this drug would be studied in combination regimens, yet the mechanism here is novel. So I'd say pinning down my exact bar is somewhat hard. What I can tell you is that at 10%-20%, you'd be holding a very compelling molecule.

Aydin Huseynov

analyst
#20

Got it. Yes, that's logical. That's logical. Okay, understood. Thanks a lot for fielding questions, and congrats on the progress.

Richard Miller

executive
#21

Thanks, Aydin.

Jeff Jones

analyst
#22

Good afternoon, everyone, and thank you for the question. Richard, I have a quick one about that press release tied to ASH for the updated data. Do you have a sense of when that announcement might come out? And on the data side, as Aydin mentioned, you've shown an ORR of roughly 43% before, or about 40%, and there's an ASH abstract with a similar ORR. So, similar to what was just asked about RCC, how are you thinking about the efficacy bar for soquelitinib in PTCL?

Richard Miller

executive
#23

As for when we announce it, we'd release that alongside the poster disclosure, so around Wednesday, December ninth, or thereabouts. On the data, I'd say it's pretty consistent. Now, you asked what I'd consider a good response. Anything above 25%, with durability and safety, as an oral drug, I'd consider a good outcome.

Jeff Jones

analyst
#24

Okay, that's helpful. Now, on the topic of partnerships—you brought this up in your prepared remarks—would those be limited to soquelitinib in autoimmune inflammation indications, or could you also look at oncology partnerships for soquelitinib or other oncology programs, perhaps on a territory-by-territory basis?

Richard Miller

executive
#25

Jeff, the way we see it right now is that inflammation and immune disease represents a strong partnering opportunity, because we have a group of backup molecules that are very close to entering the clinic. We know they work in animal models. They have favorable pharmaceutical properties; they're distinct from the oncology molecule, which many people are interested in. And, you know, it's such a novel approach and potentially better than the other approaches, as Dr. Rosenbaum mentioned. Our intellectual property portfolio is quite robust, in my view. We're seeing meaningful inbound interest already around partnerships for the immunology side of the program—the immune disease portion. That appeals to us since, as you're aware, our area of expertise spans cancer along with autoimmune conditions, and autoimmune conditions come in numerous forms, reaching across fields including pulmonary medicine, dermatology, rheumatology, and so on. Given where we are as a company and the resources we have, we believe teaming up on the immune disease elements is the most logical path, which frees us to keep our attention on T-cell lymphoma and solid tumors. So that's roughly where our strategy stands at present. Sure—that could shift based on how much partners want in, and similar factors. Is that what you were asking?

Jeff Jones

analyst
#26

Yeah. No, I appreciate that. Thank you, Richard — I'll get back in line for another turn.

Roger Song

analyst
#27

Great. Thanks for the update, and thanks for taking our question. Maybe a quick one — actually two quick questions. The first: Rich, you mentioned that a Phase III PTCL trial will kick off in the second quarter of next year. Could you help us understand what still needs to happen before it starts? I believe you mentioned IRB approval. Are there any other logistical steps that have to be finished? And the second quick question concerns the runway and the funding. Your runway extends into the later part of 2024, and you're launching Phase III. How should we think about paying for the Phase III? Thank you.

Richard Miller

executive
#28

Okay. Thanks, Roger. On the first part — the answer to that first question — from a regulatory standpoint, the protocol, all of that sort of thing, everything is done. The reason it takes a few months to finish protocols and get them through IRBs: most institutions these days have not only an IRB but also a research committee, so it's simply the paperwork involved in getting through these centers. We don't expect any problem. Most of these institutions today will not evaluate — they will not consider — a study unless it has already gone through the FDA approval process, and we've done that. So really, there are no hurdles when it comes to getting the study underway. As I said, we've had a very good response from people who want to be involved in the study — really the best people in the country. I'll let Leiv answer the second question.

Leiv Lea

executive
#29

Alright Roger, we recognize that extra funding will be necessary. That said, the wide-ranging promise of soquelitinib across oncology as well as inflammatory and immune-mediated conditions has us quite enthusiastic. So, like Richard said, this creates partnering chances for us. We think our pipeline of innovative offerings targeting sizable markets across various cancer and immune disease spaces will let us secure financing for Corvus in a way that serves both the business and its shareholders; therefore, we're pleased with our product candidates, we're really energized about soquelitinib, and we will obtain funding for the company as suitable to serve both the business and the shareholders.

Roger Song

analyst
#30

Yep, that's clear. Appreciate you taking my question.

Richard Miller

executive
#31

Okay. I believe there aren't any further questions coming in. So I'd like to express my gratitude to all of you for joining this call. We're eager to share news about what we accomplish going forward. Thank you all.

Operator

operator
#32

That brings us to the end of today's call. You're free to hang up now, and we appreciate your joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.